Smith & Nephew plc (LON:SN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,041.71 ($13.98) and traded as high as GBX 1,088.50 ($14.61). Smith & Nephew shares last traded at GBX 1,077.50 ($14.46), with a volume of 1,325,064 shares.
Smith & Nephew Stock Down 0.5%
The business has a 50-day simple moving average of GBX 1,051.38 and a two-hundred day simple moving average of GBX 1,041.71. The company has a market cap of £11.81 billion, a price-to-earnings ratio of 38.79, a PEG ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22.
Insiders Place Their Bets
In other Smith & Nephew news, insider Sybella Stanley acquired 3,810 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of GBX 1,101 ($14.77) per share, for a total transaction of £41,948.10 ($56,291.06). Also, insider Jeremy (Jez) Maiden acquired 1,855 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was acquired at an average price of GBX 1,070 ($14.36) per share, for a total transaction of £19,848.50 ($26,635.13). Insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
